Related Experiment Video
Updated: Sep 20, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Cognitive Function as a Predictor of Short-Term Pharmacological Treatment Response in Major Depressive Disorder:
Seon Hee Hwang1,2, Myung Sun Kim2, Byung Joo Ham1,3
1Department of Psychiatry, Korea University Anam Hospital, Seoul, Republic of Korea.
Objective:
Deficits in social cognition (mentalization) and other cognitive deficits have been reported in patients with major depressive disorder (MDD) and may influence treatment response. This study examined the impact of cognitive function on treatment response of patients with MDD after 8 weeks of medication and whether the impact was mediated by mentalization.
Methods:
Cognitive function (memory, attention, executive function, processing speed) and mentalization were measured in 28 patients with MDD at baseline using neuropsychological tests and self-report scales. The treatment response was defined as the rate of improvement in symptom severity and global function.
Results:
Multiple regression analyses, controlling for mentalization and cognitive function, separately revealed that delayed recall was a negative predictor of functional improvement after 8 weeks of treatment, while mentalization was a positive predictor. A single mediation model using PROCESS macro showed that delayed recall and Digit Span backward indirectly affected functional improvement, mediated by mentalization. When age at onset was controlled for as a covariate, the mediating effect lost significance, and the direct effect of delayed recall on functional improvement was still significant.
Conclusion:
Despite the small sample size, our results provide evidence that patients with MDD and low memory (delayed recall) at baseline may benefit more from short-term pharmacological treatments.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
The Influence of Cognition on Affect
Cognitive Therapy
Drug Therapy
Antianxiety Medications
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

